Valuation: BioNTech SE

Market Cap 21.88B 122B 24.53B 20.39B 18.55B 34.94B 2,362B 35.19B 246B 95.83B 1,206B 92.08B 90.09B 3,875B P/E 2026 *
-15.3x
P/E 2027 * -16x
Enterprise Value 10.51B 58.79B 11.78B 9.79B 8.91B 16.78B 1,135B 16.91B 118B 46.04B 579B 44.24B 43.28B 1,862B EV / Sales 2026 *
5.82x
EV / Sales 2027 * 6.54x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-2.98%
1 week-5.58%
Current month-3.98%
1 month-6.30%
3 months-1.38%
6 months+5.33%
Current year-6.61%
1 week 29.79
Extreme 29.79
32.15
1 month 29.79
Extreme 29.79
34.15
Current year 25.78
Extreme 25.78
41
1 year 25.78
Extreme 25.78
41
3 years 25.78
Extreme 25.78
49.05
5 years 25.78
Extreme 25.78
66.08
10 years 25.78
Extreme 25.78
66.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.98%-5.58% - - 24.53B
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.85%-2.50%+21.68%+76.90% 56.95B
+2.59%+1.16%+6.03%+37.72% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.48%-0.15%+55.04%+128.62% 43.73B
Weighted average by Cap. +1.89%-0.46%+58.98%+137.09%

Financials

2026 *2027 *
Net sales 1.81B 10.1B 2.03B 1.68B 1.53B 2.88B 195B 2.91B 20.34B 7.91B 99.56B 7.6B 7.44B 320B 1.81B 10.13B 2.03B 1.69B 1.54B 2.89B 196B 2.91B 20.39B 7.93B 99.79B 7.62B 7.46B 321B
Net income -1.38B -7.7B -1.54B -1.28B -1.17B -2.2B -149B -2.21B -15.5B -6.03B -75.85B -5.79B -5.67B -244B -1.31B -7.33B -1.47B -1.22B -1.11B -2.09B -141B -2.11B -14.75B -5.74B -72.2B -5.51B -5.4B -232B
Net Debt -11.37B -63.58B -12.74B -10.59B -9.64B -18.15B -1,227B -18.29B -128B -49.79B -626B -47.84B -46.81B -2,013B -10.03B -56.08B -11.24B -9.34B -8.5B -16.01B -1,083B -16.13B -113B -43.92B -553B -42.2B -41.29B -1,776B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
05/10/26 R$30.65 -2.98% 969
02/10/26 R$31.59 -0.38% 3,959
01/10/26 R$31.71 -0.66% 2,215
30/09/26 R$31.92 -0.56% 136
29/09/26 R$32.10 -1.11% 1,892
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
87.10EUR
Average target price
103.17EUR
Spread / Average Target
+18.44%

Quarterly revenue - Rate of surprise